A Phase II/III, Multicenter, Randomized, Double-blind, Placebo-controlled Study To Assess The Efficacy And Safety Of Tocilizumab Versus Placebo In Patients With Systemic Sclerosis
收藏DataCite Commons2025-05-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00007128/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This multicenter, randomized, double-blind, placebo-controlled, two-arm, parallel-group study
will evaluate the efficacy and safety of RoActemra/Actemra (tocilizumab) in participants with
systemic sclerosis. Participants will be randomized to receive either RoActemra/Actemra 162
mg subcutaneously weekly or placebo for 48 weeks. From Week 48 to Week 96, all participants
will receive open-label RoActemra/Actemra 162 mg subcutaneously weekly. Anticipated time on
study treatment is 96 weeks.
提供机构：
Vivli
创建时间：
2021-05-10
